Clinical Compendium: Metastatic Squamous Non-Small Cell Lung Cancer

Target Audience
This activity is intended for a national audience of oncologists, nurse practitioners, nurses, physician assistants, and other clinicians.

Program Overview

CONTENT AREAS
Squamous NSCLC pathobiology, clinical behavior, and histopathologic subtyping
Biomarker testing in advanced squamous NSCLC
Recent changes to the NCCN guidelines regarding molecular testing
Therapeutic options for frontline treatment based on molecular testing results
Optimizing treatment
Management of adverse effects

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain the key clinicopathological features of squamous non-small cell lung cancer (NSCLC) based on established and emerging immunogenomic classification concepts
Discuss molecular-testing guidelines for metastatic squamous NSCLC, including guideline-directed, evidence-based best practices for molecular testing in clinical practice
Develop treatment plans for patients with advanced squamous NSCLC, in alignment with the latest clinical efficacy and safety data
Employ strategies for the timely identification, monitoring, and management of adverse effects with the latest guideline-directed therapies recommended for use in patients with advanced squamous NSCLC